Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways
- PMID: 30251630
- DOI: 10.1016/j.chembiol.2018.05.016
Combined Proteomic and In Silico Target Identification Reveal a Role for 5-Lipoxygenase in Developmental Signaling Pathways
Abstract
Identification and validation of the targets of bioactive small molecules identified in cell-based screening is challenging and often meets with failure, calling for the development of new methodology. We demonstrate that a combination of chemical proteomics with in silico target prediction employing the SPiDER method may provide efficient guidance for target candidate selection and prioritization for experimental in-depth evaluation. We identify 5-lipoxygenase (5-LO) as the target of the Wnt pathway inhibitor Lipoxygenin. Lipoxygenin is a non-redox 5-LO inhibitor, modulates the β-catenin-5-LO complex and induces reduction of both β-catenin and 5-LO levels in the nucleus. Lipoxygenin and the structurally unrelated 5-LO inhibitor CJ-13,610 promote cardiac differentiation of human induced pluripotent stem cells and inhibit Hedgehog, TGF-β, BMP, and Activin A signaling, suggesting an unexpected and yet unknown role of 5-LO in these developmental pathways.
Keywords: Wnt pathway; cell-based screening; lipoxygenase; target identification; target prediction.
Copyright © 2018 Elsevier Ltd. All rights reserved.
Similar articles
-
5-Lipoxygenase is a candidate target for therapeutic management of stem cell-like cells in acute myeloid leukemia.Cancer Res. 2014 Sep 15;74(18):5244-55. doi: 10.1158/0008-5472.CAN-13-3012. Epub 2014 Jul 31. Cancer Res. 2014. PMID: 25082812
-
Regulation of tumorigenic Wnt signaling by cyclooxygenase-2, 5-lipoxygenase and their pharmacological inhibitors: A basis for novel drugs targeting cancer cells?Pharmacol Ther. 2016 Jan;157:43-64. doi: 10.1016/j.pharmthera.2015.11.001. Epub 2015 Nov 6. Pharmacol Ther. 2016. PMID: 26549540 Review.
-
Molecular pharmacological profile of the nonredox-type 5-lipoxygenase inhibitor CJ-13,610.Br J Pharmacol. 2004 Jul;142(5):861-8. doi: 10.1038/sj.bjp.0705860. Epub 2004 Jun 14. Br J Pharmacol. 2004. PMID: 15197110 Free PMC article.
-
Dual Role of 5-Lipoxygenase in Osteoclastogenesis in Bacterial-induced Apical Periodontitis.J Endod. 2016 Mar;42(3):447-54. doi: 10.1016/j.joen.2015.12.003. Epub 2016 Jan 7. J Endod. 2016. PMID: 26778267
-
5-lipoxygenase: a promising drug target against inflammatory diseases-biochemical and pharmacological regulation.Curr Drug Targets. 2014 Apr;15(4):410-22. doi: 10.2174/1389450114666131209110745. Curr Drug Targets. 2014. PMID: 24313690 Review.
Cited by
-
Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization.ACS Cent Sci. 2021 May 26;7(5):841-857. doi: 10.1021/acscentsci.0c01624. Epub 2021 Apr 28. ACS Cent Sci. 2021. PMID: 34079900 Free PMC article.
-
Mfsd8 Modulates Growth and the Early Stages of Multicellular Development in Dictyostelium discoideum.Front Cell Dev Biol. 2022 Jun 9;10:930235. doi: 10.3389/fcell.2022.930235. eCollection 2022. Front Cell Dev Biol. 2022. PMID: 35756993 Free PMC article.
-
Modulation of microRNA processing by 5-lipoxygenase.FASEB J. 2021 Feb;35(2):e21193. doi: 10.1096/fj.202002108R. Epub 2020 Nov 17. FASEB J. 2021. PMID: 33205517 Free PMC article.
-
Validation strategies for target prediction methods.Brief Bioinform. 2020 May 21;21(3):791-802. doi: 10.1093/bib/bbz026. Brief Bioinform. 2020. PMID: 31220208 Free PMC article. Review.
-
MLL-AF4 upregulates 5-lipoxygenase expression in t(4;11) leukemia cells via the ALOX5 core promoter.Front Pharmacol. 2025 Jan 14;15:1520507. doi: 10.3389/fphar.2024.1520507. eCollection 2024. Front Pharmacol. 2025. PMID: 39877387 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials